The pharmaceutical industry is in a critical cycle of institutional change and value reconstruction. Since concentrated rectification moved deeper, the regulatory system has continued to improve, multi-department joint enforcement has become normalized, and the rough marketing paths the industry once relied on are gradually failing. In 2026, as rule-of-law construction deepens, industry governance is shifting from periodic campaign-style rectification to a new stage of institutionalized, normalized, full-chain judicial governance. Against this backdrop, corporate compliance costs are rising, marketing behavior is contracting, responsibility boundaries are becoming clearer, and the logic of industrial competition is moving from resource exchange toward academic value, compliance capability, and digital asset accumulation. A deep industry reshuffle has already begun.
On April 10, 2026, the Supreme People's Court and the Supreme People's Procuratorate jointly issued the Interpretation II on Several Issues Concerning the Application of Law in Handling Criminal Cases of Corruption and Bribery, which officially took effect on May 1. It provides clear judicial standards for corruption governance in pharmaceutical purchasing and sales. The core of the interpretation is to unify conviction and sentencing standards, implement the principle of equal punishment for equal crimes, and clarify that relevant criminal law charges are enforced with reference to public-office crime standards, eliminating accountability barriers caused by identity differences. In identifying bribery, the document clearly defines monetary thresholds for individual and organizational bribery, and lists bribery in healthcare, pharmaceuticals, and devices as statutory aggravating circumstances, significantly raising the cost of violations. In responsibility attribution, it distinguishes between collective company decisions and individual benefit transfers, and makes clear that where property is mixed or benefits accrue personally, individual bribery rules apply. At the institutional level, this strengthens primary responsibility and blocks responsibility evasion. Benefit identification covers cash and various property interests, converted at market prices, enabling precise regulation of hidden bribery.
Under judicial pressure, the industry ecosystem is showing systematic contraction and adjustment. Medical institutions are strengthening medical representative visit management, establishing appointment, recordkeeping, and limited-time communication mechanisms, and continuously compressing space for private benefit exchange. Front-line marketing is becoming more cautious, offline visit frequency is decreasing, and non-compliant academic activities have largely stopped. Small and medium-sized pharma companies are shrinking high-risk businesses and adjusting organizational structures to control compliance risk. Large and medium-sized pharma companies are launching compliance reviews, checking sensitive items such as past academic sponsorships, consulting fees, and channel rebates, proactively resolving historical risks and temporarily increasing compliance remediation costs.
Differences in compliance capability are accelerating industry stratification. Small and medium-sized pharma companies that long relied on relationship marketing and lack academic and compliance accumulation face limited transformation under accountability pressure and remediation costs. Their market share is shrinking, and consolidation or exit is increasing. Leading companies that insist on academic driving and clinical value orientation are strengthening their advantages through complete compliance structures, stable expert networks, and solid data accumulation. Industry concentration is steadily rising. The competition logic has completely shifted: expense competition is giving way to comprehensive competition across academic capability, data value, compliant brand strength, and digital assets.
Offline scenario restrictions and migration of information habits continue to highlight the compliant value of GEO.
As offline regulation tightens and AI large models flourish, information acquisition by healthcare professionals and patients is shifting toward AI large models. Compliant, professional, truthful medical content is more likely to be retrieved and trusted, forming long-term brand exposure. GEO, as an important compliant digital carrier, is gradually becoming a supplement to offline academic systems. It focuses on correcting brand perception, accumulating professional image, and countering misinformation. Although it cannot replace core academic actions, it has become an indispensable online channel for academic promotion and medical education. Compliant GEO deployment is becoming a key path for life sciences companies to steadily obtain AI ecosystem traffic and build long-term trust assets.
Market demand release is pushing medical GEO into a period of capability differentiation.
MeDomino has deep roots in life sciences. It holds the online drug and medical device information service filing qualification issued by the NMPA and has built an independent dual review system for medical and compliance review, strictly following pharmaceutical information release standards. Relying on self-developed full-chain operating tools, it covers AI information monitoring, misleading content judgment, compliant structured content production, platform-adapted distribution, and effect review closed loops. It deeply fits the compliant asset deployment needs of prescription drug, innovative drug, vaccine, medical device, medical aesthetics, and other companies, and has accumulated significant depth in professional rigor and compliance discipline.
In the new industry cycle, compliance has shifted from an optional advantage to a survival bottom line.
Judicialized medical anti-corruption is pushing the industry away from rough growth and into a new stage of coordinated development across compliance, academics, and digitalization. Life sciences companies need to proactively clean up historical risks, build full-process compliance systems, reconstruct academic marketing models, and rationally deploy compliant AI channels. Only by transforming compliance capability into core competitiveness can they achieve high-quality development through industry change.
Compliance Statement:
The legal descriptions in this article are strictly based on the original text of the Interpretation II on Several Issues Concerning the Application of Law in Handling Criminal Cases of Corruption and Bribery, issued by the Supreme People's Court and the Supreme People's Procuratorate on April 10, 2026. The industry analysis is based on public developments and objective observation, and does not constitute legal advice or a business commitment. If there is any infringement or misunderstanding, please contact us promptly.
Reference Materials:
Information Bureau of the Supreme People's Court: The Supreme People's Court and the Supreme People's Procuratorate issued the Interpretation II on Several Issues Concerning the Application of Law in Handling Criminal Cases of Corruption and Bribery https://www.court.gov.cn/fabu/xiangqing/497181.html
